Actively Recruiting
Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential
Led by Regina Elena Cancer Institute · Updated on 2025-02-04
256
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Through genomic and transcriptomic sequencing techniques (whole exome sequencing, WES; whole transcriptome sequencing, WTS) patients with enrichment for KEAPness and specific gene interactions associated with it.
CONDITIONS
Official Title
Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Histological diagnosis of non-small cell lung cancer (NSCLC)
- Metastatic disease present
- Adequate biological material available before any anti-tumor treatment (surgery or biopsy)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate blood, liver, and kidney function
- Measurable disease according to RECIST criteria
- Availability of follow-up data for at least 6 months or until death or disease progression
- Written informed consent for study participation and data processing
You will not qualify if you...
- Previous systemic therapy for metastatic disease
- Comorbidities not controlled by adequate medical treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS National Cancer Institute "Regina Elena"
Rome, Italy, 00144
Actively Recruiting
Research Team
M
Marcello Maugeri Saccà, Medical Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here